Page 274 - SAHCS HIVMed Journal Vol 20 No 1 2019

Page 10 of 10 Original Research

21. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) 35. Shah R, Ramjee G, Kityo C, et al. Safety and efficacy of TDF/FTC/RPV and TDF/FTC/
versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled EFV – 48 week subgroup-analyses from the SALIF study. Abstract 112 presented
results from the phase 3 double-blind randomized ECHO and THRIVE trials. J at: 11th INTEREST Workshop; 2017 May 16–19; Lilongwe, Malawi. Reviews in
Acquir Immune Defic Syndr. 2012;60(1):33–42. https://doi.org/10.1097/ Antiviral Therapy & Infectious Diseases 2017_2. Amsterdam: Global Health and
QAI.0b013e31824d006e Development (AIGHD); 2017.
22. Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/ 36. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and
tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor prevention of HIV infection in adults: 2016 recommendations of the International
antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. Antiviral Society-USA Panel. JAMA. 2016;316(2):191–210. https://doi.org/10.1001/
AIDS. 2014;28(3):335–344. https://doi.org/10.1097/QAD.0000000000000087 jama.2016.8900
23. Rokx C, Verbon A, Rijnders BJ. Short communication: Lipids and cardiovascular risk 37. McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression
after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to after 12 months of antiretroviral therapy in low- and middle-income countries: A
rilpivirine/emtricitabine/tenofovir-DF. AIDS Res Hum Retroviruses. 2015;31(4): systematic review. Bull World Health Organ. 2013;91(5):377‒385E. https://doi.
363–367. https:// doi.org/10.1089/aid.2014.0278 org/10.2471/BLT.12.112946
24. van Lunzen J, Antinori A, Cohen CJ, et al. Rilpivirine vs. efavirenz-based single- 38. Pinnetti C, Di Giambenedetto S, Maggiolo F, et al. Switching to coformulated
tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from
randomized phase 3b study. AIDS. 2016;30(2):251–259. https://doi.org/10.1097/ a multicenter cohort. J Acquir Immune Defic Syndr. 2015;70(4):e147–e150.
QAD.0000000000000911 https://doi.org/10.1097/QAI.0000000000000727
25. Collins SE, Grant PM, Uwinkindi F, et al. A randomized switch from nevirapine-based 39. Lewis JM, Smith C, Torkington A, et al. Real-world persistence with antiretroviral
antiretroviral therapy to single tablet rilpivirine/emtricitabine/tenofovir disoproxil therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
fumarate in virologically suppressed human immunodeficiency virus-1-infected J Infect. 2017;74(4):401–407. https://doi.org/10.1016/j.jinf.2017.01.012
Rwandans. Open Forum Infect Dis. 2016;3(3):ofw141. eCollection 2016 Sep.
26. European Medicines Agency. Eviplera EPAR and SmPC. [updated 2017 Dec 19; cited 40. Häggblom A, Lindbäck S, Gisslén M, et al. HIV drug therapy duration; a Swedish
real world nationwide cohort study on InfCareHIV 2009–2014. PLoS One.
2018 Nov] Available from: http://www.ema.europa.eu/docs/en_GB/document_ 2017;12(2):e0171227. https://doi.org/10.1371/journal.pone.0171227
library/EPAR_-_Product_Information/human/002312/WC500118802.pdf
27. Gilead Sciences. Complera prescribing information. 2017 [cited 2019 Apr 2]. Available 41. Gianotti N, Maggiolo F, Cozzi-Lepri A, et al. Durability of RPV- and INSTI-based 1st-
line regimens in HIV-infected patients starting ART with a VL <100 000 copies/mL:
from: http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/complera/complera_ Data from the ICONA Foundation Study. Abstract MOPEB0300. Presented at: IAS;
pi.ashx. 2017 Jul 23–26; Paris, France. New York: Wiley; 2017.
28. European Medicines Agency. Edurant EPAR and SmPC. 2018. [cited 2018 Nov]. 42. Sculier D, Gayet-Ageron A, Battegay M, et al. Rilpivirine use in the Swiss HIV cohort
Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Product_Information/human/002264/WC500118874.pdf. study: A prospective cohort study. BMC Infect Dis. 2017;17(1):476. https://doi.
org/10.1186/s12879-017-2579-2
29. Tran AH, Best BM, Stek A, et al. Pharmacokinetics of rilpivirine in HIV-infected
pregnant women. J Acquir Immune Defic Syndr. 2016;72(3):289–296. https://doi. 43. Raffi F, Orkin C, Clarke A, et al. Brief report: Long-term (96-week) efficacy
org/10.1097/QAI.0000000000000968 and safety after switching from tenofovir disoproxil fumarate to tenofovir
alafenamide in HIV-infected, virologically suppressed adults. J Acquir
30. Colbers A, Schalkwijk S, Konopnicki D, et al. Substantially lower rilpivirine plasma Immune Defic Syndr. 2017;75(2):226–231. https://doi.org/10.1097/QAI.
concentrations during pregnancy. Abstract 754 presented at: Conference on 0000000000001344
Retroviruses and Opportunistic Infections; 2017 Feb 13–16; Seattle, WA. Seattle,
WA: CROI Foundation/IAS–USA; 2017. 44. Walensky RP, Horn TH, Paltiel AD. The epi-TAF for tenofovir disoproxil
fumarate? Clin Infect Dis. 2016;62(7):915–918. https://doi.org/10.1093/cid/
31. Osiyemi O, Yasin S, Zorrilla C, et al. Pharmacokinetics of total and unbound civ1000
Rilpivirine in HIV-1–infected pregnant women. Abstract 35 presented at: 7th
International Workshop on HIV & Women; 2017 Feb 11–12; Seattle, WA. 45. Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: Switch to DTG+RPV
Amsterdam: Virology Education; 2017. [cited 2019 Apr 2] Available from: http:// maintains virologic suppression through 48 wks. Abstract 44LB. Presented at:
regist2.virology-education.com/2017/7hivwomen/Abstractbook.pdf. Conference on Retroviruses and Opportunistic Infections; 2017 Feb 13–16;
Seattle, WA. Seattle, WA: CROI Foundation/IAS–USA; 2017.
32. The Antiretroviral Pregnancy Registry. Interim Report: 1 January 1989 through 31
January 2018 [issued 2018 Jun; cited 2019 Apr 2]. Available from: http://www. 46. World Health Organization. Consolidated guidelines on the use of antiretroviral
apregistry.com/forms/interim_report.pdf. drugs for treating and preventing HIV infection. Recommendations for a public
health approach. Second edition 9 June 2016. [cited 2019 Apr 2] Available
33. Panel on treatment of HIV-infected pregnant women and prevention of perinatal from: http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_
transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1- eng.pdf.
infected women for maternal health and interventions to reduce perinatal HIV
transmission in the United States. [cited 2019 Apr 2]. Available from: http:// 47. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in
aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS.
34. Munderi P, Were E, Avihingsanon A, et al. SALIF trial: Switching suppressed first- 2013;27(6):939–950. https://doi.org/10.1097/QAD.0b013e32835cee6e
line patients to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is non-inferior 48. Ford N, Shubber Z, Pozniak A, et al. Comparative safety and neuropsychiatric
to TDF/FTC/efavirenz (TDF/FTC/EFV) and could be an alternative treatment option adverse events associated with efavirenz use in first-line antiretroviral
in LMICs. Abstract THAB0104 presented at: AIDS; 2016 Jul 18–22; Durban, therapy: A systematic review and meta-analysis of randomized trials. J
South Africa. New York: Wiley; 2016 [cited 2018 Apr 2] Available from https:// Acquir Immune Defic Syndr. 2015;69(4):422‒429. https://doi.org/10.1097/
onlinelibrary.wiley.com/doi/epdf/10.7448/IAS.19.6.21264. QAI.0000000000000606

http://www.sajhivmed.org.za 267 Open Access